Phase III, Multicenter, Open-label, Randomized Trial of Tarceva (Rm) vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR

Trial Profile

Phase III, Multicenter, Open-label, Randomized Trial of Tarceva (Rm) vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Cisplatin; Docetaxel; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms EURTAC
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2015 Results from a meta-analysis of 6 trials showing impact on overall survival in patients with EGFR mutations presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 14 Jun 2013 Based on results of this study, erlotinib was approved in Japan for chemotherapy-naive, unresectable, recurrent/advanced NSCLC with EGFR mutations, according to a Chugai Pharmaceutical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top